title: [Composition of the Belgian influenza vaccines for the 2015-2016 season].
abstract: This article gives an update on how the composition of the influenza virus vaccine is determined, how the infection spreads, and what the consequences are of the disease. Next flu season for the first time a quadrivalent and intranasal vaccine will be available on the Belgian market. What is the difference with what we know until now? Is there an added value? How about the contraindications? Furthermore we elaborate on the composition of the influenza vaccine on the Belgian market for the season 2015-2016 and we give a reminder of the patient groups with a high risk for complications. As pharmacists we should motivate these patients to get themselves vaccinated. Finally, we discuss the reimbursement conditions of the National Institute for Health and Disability Insurance INIHDII.
authors.forename: M
authors.initials: M
authors.lastname: Van Steenkiste
mesh_terms: D001530:Belgium; D006801:Humans; D007252:Influenza Vaccines / Q000737:chemistry / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control*; D012621:Seasons; D014611:Vaccination
chemical_list: D007252:Influenza Vaccines